PepBank has 3 Prostamax studies with results. All of them gave Prostamax, with 9 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 9 results and 5 papers. Newer studies from Europe PMC
Identifiers, parent molecule, targets and development stage, from curated data.
Prostamax is a synthetic 4-residue peptide in the Khavinson bioregulator family. Its sequence is Lys-Glu-Asp-Pro. Chemical identity does not establish a clinical benefit or a safe human dose.
No molecular target is recorded for this peptide.
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
4 amino acids
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
pI 4.18 · Net charge at pH 7.4: −1.06
Point or use arrow keys
Henderson-Hasselbalch, EMBOSS pKa set. Calculated, not measured.
| pH | Net charge |
|---|---|
| 0 | 2.00 |
| 1 | 2.00 |
| 2 | 1.96 |
| 3 | 1.61 |
| 4 | 0.28 |
| 5 | −0.78 |
| 6 | −0.98 |
| 7 | −1.02 |
| 8 | −1.20 |
| 9 | −1.73 |
| 10 | −2.10 |
| 11 | −2.61 |
| 12 | −2.94 |
| 13 | −2.99 |
| 14 | −3.00 |
4 residues. Each residue counts in one class; F and W count as aromatic.
No 3D structure
No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.
Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).
SMILES fromPubChem CID 9848296(opens in a new tab)
C1C[C@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N)C(=O)OPeople first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Counts are exact and come from studies that gave the peptide.
Studies by year
3 of 5 studies have results (60%), published 2004 to 2012. Top row: every study. Bottom row: studies with results about Prostamax (KEDP), by class. The rows use different scales.
Studies5 in all, 2004 to 2012
Studies with results3 in all, 2004 to 2012
Retracted studies are left out. A study with results in two classes counts in both.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.
0 trials match. Highest phase first. Data from ClinicalTrials.gov.
No trial matches these filters.
Studies on this peptide. Some have results. The others have none yet.
5 studies match. Retracted studies are left out.
Showing 3 of 5 studiesquery qry_f843d1a7ef5b2f22a1e11aaf
3 studies
In vitro (cells) · 2004
VKh et al. 2004Bulletin of experimental biology and medicinecited by 2
PMID 15085253DOI 10.1023/b:bebm.0000024393.40560.05PUB-15085253
In vitro (cells) · 2004
Meskhi et al. 2004Biofizika
PMID 15612551PUB-15612551
In vitro (cells) · 2012
Dzhokhadze et al. 2012Georgian medical news
PMID 23221144PUB-23221144
These studies name Prostamax (KEDP) but give no result for it (for example, the results concern another peptide in the study).
Indexing hint: Animal study · 2006
Zakutskiĭ et al. 2006Advances in gerontology = Uspekhi gerontologii
PMID 17152728PUB-17152728
PubMed tag: none · 2009
Kiladze et al. 2009Georgian medical news
PMID 19359734PUB-19359734
Page 1 of 1
Khavinson VKh · Bulletin of experimental biology and medicine · 2004
In vitro (cells) · 8 results
Dzhokhadze TA · Georgian medical news · 2012
In vitro (cells) · 3 results
Meskhi T · Biofizika · 2004
In vitro (cells) · 5 results
Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.
| Jurisdiction | Body | Status | As of | Source |
|---|---|---|---|---|
| US | FDA | The cited Drugs@FDA query returned no matches for Prostamax or Lys-Glu-Asp-Pro as brand or active ingredient. Other spelling variants were not checked. This search does not establish complete FDA approval status. Compounding status remains unresolved. | 21 Oct 2026 | api.fda.gov (opens in a new tab) |
| EU | EMA | The EMA central dataset contained 2754 records. No record matched Prostamax, Prostamaks, Lys-Glu-Asp-Pro or CAS 473578-47-1. This check does not establish all EU approvals. National authorisations remain unresolved. | 21 Oct 2026 | ema.europa.eu (opens in a new tab) |
| Sport | WADA | Status unknown The peptide is not named in the 2026 list. | 2026 List | wada-ama.org (opens in a new tab) |
| Russia | Note | Human medicine registration was not established. The Russian medicine register was accessible, but a complete name and formulation search remains unresolved. | 21 Oct 2026 | grls.rosminzdrav.ru (opens in a new tab) |
Reported effects from study results.
No safety results from studies in people
The doses that these studies used. They are not recommendations.
No dose was reported in the study results.
PepBank is a research reference. Talk to a doctor before you use any peptide.
Data version, change history and code for this peptide.
curl -s https://Evidence summary for Prostamax (KEDP): counts by class, key results with sources, notices, data version.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Top outcomes
The 2 outcome groups with the most study results, by evidence class.
Data version 308560. Bar length is the number of results, not the size of an effect.
Evidence matrix
Study results by outcome and evidence class. Arrows show how the measured outcome moved, not whether the change is good.
| Outcome group | Human | Animal | Lab | Computer model | Total |
|---|---|---|---|---|---|
| Receptor activity and mechanismPharmacology | No results | No results | Lab: 6 results from 2 studies: 1 increase, 4 decrease, 1 not reported. Strongest design: In vitro (cells) | No results | 6 |
| Aging markersAging and longevity | No results | No results | Lab: 3 results from 1 study: 2 increase, 1 decrease. Strongest design: In vitro (cells) | No results | 3 |
2 outcome groups shown of 2 · 9 study results
Data version 308560. Shade grows with the number of results. Every cell shows the exact count.